RxDoctor Payments Data

Mark Whitworth

Family Medicine · Pelham, ALNPI 1902369523

Payments from drug & device makers

$6,853in general payments, 2019–2025

Across 390 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$603
  • Pfizer$562
  • Novo Nordisk$487
  • GSK$487
  • Otsuka America Pharmaceutical, Inc.$480
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$6,839100%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,853 in reported general payments places this provider in the 85th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$75,552
Medicare patients
200
Services billed
1,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide96$124,170
OzempicSemaglutide97$97,578
RybelsusSemaglutide74$95,667
Trelegy ElliptaFluticasone/Umeclidin/Vilanter106$85,839
FarxigaDapagliflozin Propanediol93$85,074
JardianceEmpagliflozin79$74,514
EliquisApixaban42$55,881
JanuviaSitagliptin Phosphate20$20,593
Repatha SureclickEvolocumab26$18,732
MyrbetriqMirabegron14$18,056
LinzessLinaclotide26$16,836
XareltoRivaroxaban18$15,332
BelsomraSuvorexant15$8,250
Atorvastatin Calcium529$7,905
JanumetSitagliptin Phos/Metformin Hcl11$7,727

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$487$193,246171 claims
Lilly USA, LLCMounjaro$410$124,17096 claims
AstraZenecaFarxiga, Breztri Aerosphere$603$92,547105 claims
GSKTrelegy Ellipta, Anoro Ellipta$487$90,676118 claims
Boehringer IngelheimJardiance$17$74,51479 claims
PfizerEliquis$562$55,88142 claims
AbbVieLinzess, Savella$1,004$22,21237 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$102$7,15313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Pelham

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →